TRCT
NEPH icon

Tower Research Capital (TRC)’s Nephros NEPH Stock Holding History

Tower Research Capital (TRC)’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,105
Closed -$4.52K – 5475
2025
Q2 		$4.52K Sell
1,105
-1,693
-61% -$4.52K ﹤0.01% 4314
2025
Q1 		$4.81K Buy
2,798
+199
+8% +$312 ﹤0.01% 4192
2024
Q4 		$3.82K Sell
2,599
-192
-7% -$292 ﹤0.01% 4584
2024
Q3 		$4.77K Sell
2,791
-882
-24% -$1.74K ﹤0.01% 4428
2024
Q2 		$7.75K Sell
3,673
-728
-17% -$1.57K ﹤0.01% 4430
2024
Q1 		$9.64K Buy
4,401
+1,907
+76% +$6.05K ﹤0.01% 3821
2023
Q4 		$8.63K Buy
2,494
+2,268
+1,004% +$4.94K ﹤0.01% 4486
2023
Q3 		$334 Sell
226
-328
-59% -$488 ﹤0.01% 5600
2023
Q2 		$859 Sell
554
-10,856
-95% -$16K ﹤0.01% 5528
2023
Q1 		$12K Sell
11,410
-1,712
-13% -$1.97K ﹤0.01% 4105
2022
Q4 		$15K Sell
13,122
-1,114
-8% -$1.19K ﹤0.01% 3435
2022
Q3 		$13K Buy
14,236
+4,932
+53% +$6.97K ﹤0.01% 4277
2022
Q2 		$14K Buy
9,304
+8,856
+1,977% +$23.9K ﹤0.01% 4152
2022
Q1 		$2K Buy
448
+371
+482% +$1.76K ﹤0.01% 5575
2021
Q4 		$0 Buy
+77
New +$562 ﹤0.01% 6417
2021
Q3 		– Sell
-350
Closed -$3K – 6026
2021
Q2 		$3K Sell
350
-1
-0.3% -$8 ﹤0.01% 4939
2021
Q1 		$2K Buy
+351
New +$2.77K ﹤0.01% 5032
2020
Q4 		– Sell
-1,391
Closed -$10K – 5319
2020
Q3 		$10K Buy
1,391
+1,376
+9,173% +$10.1K ﹤0.01% 4097
2020
Q2 		$0 Sell
15
-267
-95% -$2.12K ﹤0.01% 4897
2020
Q1 		$2K Buy
+282
New +$2.39K ﹤0.01% 2609

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tower Research Capital (TRC)'s NEPH Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Nephros (NEPH) in Q3 2025, closing a stake of 1,105 shares — an estimated $4.52K sold.

Tower Research Capital (TRC) first reported a position in NEPH in Q1 2020 and held it in 20 quarters. The position peaked at $15K in Q4 2022. 24 funds tracked by Wall St. Rank hold NEPH as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Nephros position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,105 Nephros shares in Q3 2025, an estimated $4.52K.
  • Tower Research Capital (TRC) first reported a position in Nephros in Q1 2020 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Nephros position peaked at $15K in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Nephros as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.